The nine-year-old company is pursuing a unique root cause for Alzheimer's — a common bacteria in the mouth — but liver problems in some patients caused the FDA to halt part of an important clinical trial.Peninsula Alzheimer’s drug developer sheds third of value after part of trial halted
The nine-year-old company is pursuing a unique root cause for Alzheimer's — a common bacteria in the mouth — but liver problems in some patients caused the FDA to halt part of an important clinical trial.